<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">FEXOFENADINE</span><br/>(fex-o-fen'a-deen)<br/><span class="topboxtradename">Allegra<br/></span><b>Classifications:</b> <span class="classification">antihistamine</span>; <span class="classification">h<sub>1</sub>-receptor antagonist</span>; <span class="classification">non-sedating</span><br/><b>Prototype: </b>Loratadine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>30 mg, 60 mg, 180 mg tablets; 60 mg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Antihistamine competitively antagonizes histamine at the H<sub>1</sub>-receptor site; does not bind with histamine to inactivate it. Not associated with anticholinergic or sedative properties.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Inhibits antigen-induced bronchospasm and histamine release from mast cells. Efficacy is indicated by reduction of the following:
         nasal congestion and sneezing; watery or red eyes; itching nose, palate, or eyes.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Relief of symptoms associated with seasonal allergic rhinitis, and chronic urticaria.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to fexofenadine; pregnancy (category C).</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Lactation; renal and hepatic insufficiency, hypertension, diabetes mellitus, ischemic heart disease, increased ocular pressure,
         hyperthyroidism, renal impairment, or prostatic hypertrophy. Safety and effectiveness in children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Allergic Rhinitis</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute"></span> &gt;<i>12 y</i>, <span class="rdroute">PO</span> 60 mg b.i.d.<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>611</i>, 30 mg b.i.d.<br/><br/><span class="indicationtitle">Chronic Urticaria</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 60 mg b.i.d.<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> &gt;<i>6 y</i>, 30 mg b.i.d.<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> <span class="rdage">Adult:</span> <span class="rdroute">PO</span> 60 mg q.d.<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 30 mg q.d.<br/><br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Reduce starting dose for those with decreased kidney function.</li>
<li>Do not give within 15 min of an aluminum- or magnesium-containing antacid.</li>
<li>Store at 20°25° C (68°77° F). Protect from excess moisture.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span>
<span class="speceff-common">Headache,</span> drowsiness, fatigue. <span class="typehead">GI:</span> Nausea, dyspepsia, throat irritation. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">antacids</span> will decrease serum level of fexofenadine. Herbal: <b>St. John's wort</b> will decrease serum level of fexofenadine.  
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract, 33% reaches systemic circulation. <span class="typehead">Onset:</span> 1 h. <span class="typehead">Peak:</span> 23 h. <span class="typehead">Duration:</span> At least 12 h. <span class="typehead">Distribution:</span> 6070% bound to plasma proteins. <span class="typehead">Metabolism:</span> Only 5% of dose metabolized in liver. <span class="typehead">Elimination:</span> 80% excreted in urine, 11% in feces. <span class="typehead">Half-Life:</span> 14.4 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor therapeutic effectiveness, which is indicated by decreased nasal congestion, sneezing, watery or red eyes, and itching
            nose, palate, or eyes.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>
            							Note: Drug is well tolerated and causes minimal adverse effects.
            						
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>